PRA Health Sciences
4141 ParkLake Avenue, Suite 530
244 articles with PRA Health Sciences
PRA Health Sciences, Inc. Reports First Quarter 2020 Results, Withdraws Full Year 2020 Guidance Due to Uncertain COVID-19 Impact and Provides Second Quarter 2020 Guidance
PRA Health Sciences, Inc. reported financial results for the three months ended March 31, 2020..
PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its first quarter 2020 results after the market closes on Thursday, April 30, 2020.
Symphony Health to provide free access to new MetysTM COVID-19 Module for U.S. based life sciences industry during pandemicMetys COVID-19 Module delivers pharmaceutical market analytics and intelligence quickly through a single access point
PRA Health Sciences announced that Symphony Health, a PRA Health Sciences company, will make a 30-day license of its newly released MetysTM COVID-19 Module available to the U.S. life science industry at no charge.
PRA Health Sciences expands remote clinical study support with its Mobile Health Platform during COVID-19 pandemicPRA’s Mobile Health Platform delivers virtual solutions for sites and patients enrolled in trials
As a response to the ongoing global COVID-19 pandemic, PRA Health Sciences announced the expansion of its industry-leading Mobile Health Platform for remote clinical monitoring, adding several new capabilities that address sponsor needs for COVID-19 virtual study support.
Life sciences customers will gain flexibility to build bespoke, fit-for-purpose data assets and strategies to support the development and delivery of life-enhancing drugs
PRA Health Sciences, Inc. Reports Fourth Quarter and Full Year 2019 Results and Provides First Quarter and Full Year 2020 Guidance
PRA Health Sciences, Inc. reported financial results for the quarter and year ended December 31, 2019..
Perspecta and PRA Health Sciences complete successful modernization of Million Veteran Program for U.S. Department of Veterans Affairs
MVP is a national, voluntary research program funded by the VA Office of Research and Development.
PRA Health Sciences, Inc. reported financial results for the quarter ended September 30, 2019.
An industry first, the volunteer committee will evaluate unique patient needs and advise PRA on how clinical trials can be adapted for rare disease patients
PRA Health Sciences (NASDAQ: PRAH) announced today the launch of Symphony Health’s new national market measurement tool – MetysTM (pronounced Met-IS), the only completely integrated, all-in-one market research solution available from a contract research organization (CRO).
PRA Health Sciences, Inc. Expands Service Provisions to Pharmaceutical and Biotech Companies Through Buyout of Takeda Joint Venture in Japan
PRA Health Sciences, Inc. (NASDAQ: PRAH, “PRA”) announced the buyout of its joint venture with Takeda Pharmaceutical Company Limited (TSE: 4502, “Takeda”) in Japan, which was completed on June 1.
Net new business of $670.0 million; Net book-to-bill of 1.30
PRA Health Sciences, Inc. will release its second quarter results after the market closes on Wednesday, August 1, 2018.
Biotech manufacturing is the non-glamorous side of biopharma, although its impact on the economy shouldn’t be underestimated. Here's everything you need to know.
The Company will also host a conference call on Thursday, February 22, 2018 at 9:00 a.m. (ET) to discuss the results with members of the investment community.
For the three months ended September 30, 2017, service revenue was $494.6 million, which represents growth of 23.7%, or $94.7 million.
As part of Care Innovations focus on expanding into adjacent markets, the company is proud to announce its exclusive global partnership with PRA Health Sciences.